x
|
Quarterly
Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
|
o
|
Transition
Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
|
Delaware |
87-0419387
|
(State or other jurisdiction of | (I.R.S. Employer |
incorporation or organization) | Identification No.) |
Large accelerated filer o | Accelerated filer o | |
Non-accelerated filer o | (Do not check if smaller reporting company) | Smaller reporting company x |
Page
|
||
PART
I
|
FINANCIAL
INFORMATION
|
3
|
Item
1.
|
Financial
Statements
|
3
|
Unaudited Condensed Consolidated Statements of
Operations for the three and six months ended March 31, 2009 and
2008
|
3
|
|
Condensed Consolidated Balance Sheets as of
March 31, 2009 (unaudited) and September 30, 2008
|
4
|
|
Unaudited
Condensed Consolidated Statements of Cash Flows for the six months ended
March 31, 2009 and 2008
|
5
|
|
Unaudited Condensed Consolidated Statements of
Stockholders’ Equity (Deficit) for the six months ended March 31,
2009 and 2008
|
6
|
|
Notes to Unaudited Condensed Consolidated
Financial Statements
|
7
|
|
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
16
|
Item
3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
28
|
Item
4T.
|
Controls
and Procedures
|
28
|
PART
II
|
OTHER
INFORMATION
|
29
|
Item
1A.
|
Risk
Factors
|
29
|
Item
6.
|
Exhibits
|
30
|
Item
1.
|
Financial
Statements
|
For
the three months ended
March
31,
|
For
the six months ended
March
31,
|
|||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
REVENUES
|
||||||||||||||||
Laboratory
Information Services
|
$ | 31,200 | $ | 35,800 | $ | 59,700 | $ | 94,500 | ||||||||
Clinical
Services
|
152,600 | 180,600 | 295,800 | 180,600 | ||||||||||||
183,800 | 216,400 | 355,500 | 275,100 | |||||||||||||
OPERATING
EXPENSES
|
||||||||||||||||
Cost
of laboratory services revenues
|
35,600 | 59,500 | 69,100 | 97,400 | ||||||||||||
Research
and development
|
554,400 | 534,100 | 1,236,900 | 906,600 | ||||||||||||
Sales
and marketing
|
283,700 | 208,100 | 547,000 | 246,800 | ||||||||||||
General
and administrative
|
765,900 | 752,800 | 1,389,400 | 1,424,400 | ||||||||||||
Total
operating expenses
|
1,639,600 | 1,554,500 | 3,242,400 | 2,675,200 | ||||||||||||
OPERATING
LOSS
|
(1,455,800 | ) | (1,338,100 | ) | (2,886,900 | ) | (2,400,100 | ) | ||||||||
OTHER
INCOME (EXPENSE):
|
||||||||||||||||
Interest
income (expense), net
|
(4,700 | ) | 30,200 | (3,500 | ) | 84,200 | ||||||||||
Total
other income
|
(4,700 | ) | 30,200 | (3,500 | ) | 84,200 | ||||||||||
LOSS
BEFORE PROVISION FOR INCOME TAXES
|
(1,460,500 | ) | (1,307,900 | ) | (2,890,400 | ) | (2,315,900 | ) | ||||||||
Income
taxes
|
800 | -- | 2,800 | 800 | ||||||||||||
NET
LOSS
|
$ | (1,461,300 | ) | $ | (1,307,900 | ) | $ | (2,893,200 | ) | $ | (2,316,700 | ) | ||||
NET
LOSS PER SHARE:
|
||||||||||||||||
Basic
|
$ | (0.06 | ) | $ | (0.05 | ) | $ | (0.11 | ) | $ | (0.09 | ) | ||||
Diluted
|
$ | (0.06 | ) | $ | (0.05 | ) | $ | (0.11 | ) | $ | (0.09 | ) | ||||
WEIGHTED
AVERAGE SHARES OUTSTANDING:
|
||||||||||||||||
Basic
|
25,299,547 | 25,299,547 | 25,299,547 | 25,299,547 | ||||||||||||
Diluted
|
25,299,547 | 25,299,547 | 25,299,547 | 25,299,547 |
March
31, 2009
|
September
30, 2008
|
|||||||
ASSETS
|
(unaudited)
|
|||||||
CURRENT
ASSETS
|
||||||||
Cash
|
$ | 562,400 | $ | 1,997,000 | ||||
Accounts
receivable (net of allowance for doubtful
accounts
of $17,200 (unaudited) as of March 31, 2009
and
$17,200 as of September 30, 2008)
|
93,700 | 98,200 | ||||||
Prepaid
and other
|
170,400 | 189,400 | ||||||
Total
current assets
|
826,500 | 2,284,600 | ||||||
Other
assets
|
24,200 | 28,700 | ||||||
Goodwill
|
320,200 | 320,200 | ||||||
TOTAL
ASSETS
|
$ | 1,170,900 | $ | 2,633,500 | ||||
LIABILITIES
AND STOCKHOLDERS’ EQUITY
|
||||||||
CURRENT
LIABILITIES
|
||||||||
Accounts
payable (including amounts due to related
parties
of $6,800 (unaudited) as of March 31, 2009 and
$6,800
as of September 30, 2008)
|
$ | 672,200 | $ | 335,700 | ||||
Accrued
liabilities
|
335,900 | 207,500 | ||||||
Deferred
compensation (including $ 107,000 (unaudited)
and
$107,000 to related parties as of March 31, 2009 and
September
30, 2008 respectively)
|
249,200 | 264,900 | ||||||
Accrued
patient costs
|
481,100 | 397,500 | ||||||
Accrued
consulting fees
|
63,500 | 67,600 | ||||||
Accrued
interest
|
46,400 | 42,600 | ||||||
Convertible
promissory notes
|
50,000 | 50,000 | ||||||
Secured
Convertible promissory notes – related parties
|
500,000 | - | ||||||
Current
portion of long-term debt
|
92,200 | 88,500 | ||||||
Total
current liabilities
|
2,490,500 | 1,454,300 | ||||||
LONG
–TERM LIABILITIES
|
||||||||
Note
payable to officer
|
72,500 | 118,600 | ||||||
Capital
lease
|
6,700 | 7,700 | ||||||
Total
long term liabilities
|
79,200 | 126,300 | ||||||
COMMITMENTS
AND CONTINGENCIES
|
- | - | ||||||
Stockholders’
equity (deficit):
|
||||||||
Common
stock, $0.001 par value; authorized,
750,000,000
shares, issued and outstanding, 25,299,547
shares
as of March 31, 2009 and September 30, 2008
|
25,300 | 25,300 | ||||||
Additional
paid-in capital
|
18,142,800 | 17,701,300 | ||||||
Accumulated
deficit
|
(19,566,900 | ) | (16,673,700 | ) | ||||
Total
stockholders’ equity (deficit)
|
(1,398,800 | ) | 1,052,900 | |||||
TOTAL
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
$ | 1,170,900 | $ | 2,633,500 |
For
the six months ended
March
31,
|
||||||||
2009
|
2008
|
|||||||
CASH
FLOWS FROM OPERATING ACTIVITIES
|
||||||||
Net
loss
|
$ | (2,893,200 | ) | $ | (2,316,700 | ) | ||
Adjustments
to reconcile net loss to
net
cash used in operating activities:
|
||||||||
Depreciation
and Amortization
|
4,500 | 58,700 | ||||||
Stock-based
compensation
|
441,500 | 582,300 | ||||||
Changes
in operating assets and liabilities:
|
||||||||
Accounts
receivable
|
4,500 | (12,300 | ) | |||||
Prepaids
and other current assets
|
19,000 | (85,700 | ) | |||||
Accounts
payable
|
336,500 | (6,600 | ) | |||||
Accrued
liabilities
|
132,200 | 3,200 | ||||||
Deferred
compensation
|
(15,700 | ) | 163,900 | |||||
Accrued
consulting fees
|
(4,100 | ) | (20,600 | ) | ||||
Accrued
patient costs
|
83,600 | - | ||||||
Net
cash used in operating activities
|
(1,891,200 | ) | (1,633,800 | ) | ||||
CASH
FLOWS FROM INVESTING ACTIVITIES
|
||||||||
Increase
in other assets
|
- | (20,200 | ) | |||||
Cash
for acquisition, including transaction costs of $43,700
|
- | (11,600 | ) | |||||
Net
cash used in investing activities
|
- | (31,800 | ) | |||||
CASH
FLOWS FROM FINANCING ACTIVITIES
|
||||||||
Cash
from Secured Convertible notes
|
500,000 | - | ||||||
Repayment
of note
|
(42,500 | ) | (19,900 | ) | ||||
Prepayment
of lease
|
(900 | ) | (200 | ) | ||||
Deferred
offering costs
|
- | (22,900 | ) | |||||
Net
cash from financing activities
|
456,600 | (43,000 | ) | |||||
Net
decrease in cash
|
(1,434,600 | ) | (1,708,600 | ) | ||||
Cash,
beginning of period
|
1,997,000 | 5,790,100 | ||||||
Cash,
end of period
|
$ | 562,400 | $ | 4,081,500 |
SUPPLEMENTAL
DISCLOSURE OF CASH FLOW
|
||||||||
INFORMATION
|
||||||||
Cash paid
during the period for:
|
||||||||
Interest
|
$ | 7,900 | $ | 5,300 | ||||
Income
taxes
|
$ | 2,800 | $ | 800 | ||||
Fair
value of note payable to officer for acquisition
|
- | $ | 265,900 | |||||
Fair
value of equipment acquired through a lease
|
- | $ | 10,500 |
For the six months
ended March 31, 2009
|
Common
Stock
|
Additional
Paid-in
|
Accumulated
|
|||||||||||||||||
Shares
|
Amount
|
Capital
|
Deficit
|
Total
|
||||||||||||||||
BALANCE
- September 30,
2008
|
25,299,547 | $ | 25,300 | $ | 17,701,300 | $ | (16,673,700 | ) | $ | 1,052,900 | ||||||||||
Stock-
based
compensation
|
- | - | 441,500 | - | 441,500 | |||||||||||||||
Net
loss for the six months ended March 31, 2009
|
- | - | - | (2,893,200 | ) | (2,893,200 | ) | |||||||||||||
Balance
at March 31,
2009
|
25,299,547 | $ | 25,300 | $ | 18,142,800 | $ | (19,566,900 | ) | $ | (1,398,800 | ) |
For
the six months ended March 31, 2008
|
Common
Stock
|
Additional
Paid-in
|
Accumulated
|
|||||||||||||||||
Shares
|
Amount
|
Capital
|
Deficit
|
Total
|
||||||||||||||||
BALANCE
- September 30,
2007
|
25,299,547 | $ | 25,300 | $ | 16,630,000 | $ | (11,302,200 | ) | $ | 5,353,100 | ||||||||||
Stock-
based
compensation
|
- | - | 582,300 | - | 582,300 | |||||||||||||||
Net
loss for the six months ended March 31, 2008
|
- | - | - | (2,316,700 | ) | (2,316,700 | ) | |||||||||||||
Balance
at March 31,
2008
|
25,299,547 | $ | 25,300 | $ | 17,212,300 | $ | (13,618,900 | ) | $ | 3,618,700 |
For
the three months ended
March
31,
|
||||||||
2009
|
2008
|
|||||||
Operations
|
$ | 4,000 | $ | 4,000 | ||||
Research
and development
|
65,200 | 111,100 | ||||||
Sales
and marketing
|
38,200 | - | ||||||
General
and administrative
|
106,500 | 49,900 | ||||||
Total
|
$ | 213,900 | $ | 165,000 |
For
the six months ended
March
31,
|
||||||||
2009
|
2008
|
|||||||
Operations
|
$ | 8,000 | $ | 8,000 | ||||
Research
and development
|
130,400 | 186,600 | ||||||
Sales
and marketing
|
80,000 | - | ||||||
General
and administrative
|
223,100 | 387,700 | ||||||
Total
|
$ | 441,500 | $ | 582,300 |
Number
of Shares
|
Weighted
Average Exercise Price
|
|||||||
Outstanding
at September 30, 2008
|
8,964,567 | $ | 0.60 | |||||
Granted
|
24,000 | $ | 0.51 | |||||
Exercised
|
- | - | ||||||
Forfeited
|
(257,813 | ) | $ | 0.51 | ||||
Outstanding
at December 31, 2008
|
8,730,754 | $ | 0.61 | |||||
Granted
|
56,000 | $ | 0.40 | |||||
Exercised
|
- | - | ||||||
Forfeited
|
- | - | ||||||
Outstanding
at March 31, 2009
|
8,786,754 | $ | 0.60 | |||||
Weighted
average fair value of options granted during:
|
||||||||
3
months ended March 31, 2009
|
$ | 0.40 | ||||||
6
months ended March 31, 2009
|
$ | 0.43 |
Exercise
Price
|
Number
of Shares
|
Weighted
Average
Contractual
Life
|
Weighted
Average
Exercise
Price
|
|||
$0.12
|
859,270
|
10
years
|
$0.12
|
|||
$0.132
|
3,112,545
|
7
years
|
$0.132
|
|||
$0.30
|
135,700
|
10
years
|
$0.30
|
|||
$0.59
|
28,588
|
10
years
|
$0.59
|
|||
$0.80
|
140,000
|
10
years
|
$0.80
|
|||
$0.89
|
968,875
|
10
years
|
$0.89
|
|||
$0.96
|
496,746
|
10
years
|
$0.96
|
|||
$1.09
|
2,614,232
|
10
years
|
$1.09
|
|||
$1.20
|
333,611
|
5
years
|
$1.20
|
|||
$0.51
|
41,187
|
10
Years
|
$0.51
|
|||
$0.40
|
56,000
|
10
Years
|
$0.40
|
|||
Total
|
8,786,754
|
$0.60
|
||||
Fair
value of note payable issued
|
$ | 265,900 | ||
Direct
transaction costs
|
43,700 | |||
Purchase
price
|
309,600 | |||
Allocated
to net tangible liabilities,
including
cash of $32,100
|
(10,600 | ) | ||
Allocated
to goodwill
|
$ | 320,200 |
Three
Months ended March 31, 2009
|
||||||||||||||||
Laboratory
Information
Services
|
Clinic
|
Eliminations
|
Total
|
|||||||||||||
Revenues
|
$ | 34,600 | $ | 180,100 | $ | (30,900 | ) | $ | 183,800 | |||||||
Operating
expenses:
|
||||||||||||||||
Cost
of revenues
|
35,600 | 3,400 | (3,400 | ) | 35,600 | |||||||||||
Research
and development
|
554,400 | - | - | 554,400 | ||||||||||||
Sales
and marketing
|
282,300 | 1,400 | - | 283,700 | ||||||||||||
General
and administrative
|
625,100 | 168,300 | (27,500 | ) | 765,900 | |||||||||||
Total
operating expenses
|
$ | 1,497,400 | $ | 173,100 | $ | (30,900 | ) | $ | 1,639,600 | |||||||
Loss
from operations
|
$ | (1,462,800 | ) | $ | 7,000 | $ | 0 | $ | (1,455,800 | ) |
Six
Months ended March 31, 2009
|
||||||||||||||||
Laboratory
Information
Services
|
Clinic
|
Eliminations
|
Total
|
|||||||||||||
Revenues
|
$ | 66,800 | $ | 329,700 | $ | (41,000 | ) | $ | 355,500 | |||||||
Operating
expenses:
|
||||||||||||||||
Cost
of revenues
|
69,100 | 7,100 | (7,100 | ) | 69,100 | |||||||||||
Research
and development
|
1,236,900 | - | - | 1,236,900 | ||||||||||||
Sales
and marketing
|
542,900 | 4,100 | - | 547,000 | ||||||||||||
General
and administrative
|
1,106,200 | 317,100 | (33,900 | ) | 1,389,400 | |||||||||||
Total
operating expenses
|
$ | 2,955,100 | $ | 328,300 | $ | (41,000 | ) | $ | 3,242,400 | |||||||
Loss
from operations
|
$ | (2,888,300 | ) | $ | 1,400 | $ | 0 | $ | (2,886,900 | ) |
Laboratory
Information Services
|
Clinic
|
Total
|
||||||||||
Goodwill
|
$ | 320,200 | $ | - | $ | 320,200 | ||||||
Total
assets
|
$ | 1,100,600 | $ | 70,300 | $ | 1,170,900 |
For
the three months ended March 31,
|
2009
|
2008
|
||||||
Net
loss for computation of basic net loss per share
|
$ | (1,461,300 | ) | $ | (1,307,900 | ) | ||
Net
loss for computation of dilutive net loss per share
|
$ | (1,461,300 | ) | $ | (1,307,900 | ) | ||
Basic
net loss per share
|
$ | (0.06 | ) | $ | (0.05 | ) | ||
Diluted
net loss per share
|
$ | (0.06 | ) | $ | (0.05 | ) | ||
For
the six months ended March 31,
|
2009
|
2008
|
||||||
Net
loss for computation of basic net loss per share
|
$ | (2,893,200 | ) | $ | (2,316,700 | ) | ||
Net
loss for computation of dilutive net loss per share
|
$ | (2,893,200 | ) | $ | (2,316,700 | ) | ||
Basic
net loss per share
|
$ | (0.11 | ) | $ | (0.09 | ) | ||
Diluted
net loss per share
|
$ | (0.11 | ) | $ | (0.09 | ) | ||
Basic
weighted average shares outstanding
|
25,299,547 | 25,299,547 | ||||||
Dilutive
common equivalent shares
|
- | - | ||||||
Diluted
weighted average common shares
|
25,299,547 | 25,299,547 |
Anti-dilutive
common equivalent shares not included in the
computation
of dilutive net loss per share:
|
||||||||
For
the three months ended March 31,
|
2009
|
2008
|
||||||
Convertible
debt
|
4,995,000 | 4,995,000 | ||||||
Warrants
|
6,899,353 | 6,899,353 | ||||||
Options
|
8,740,087 | 8,545,578 | ||||||
For
the six months ended March 31,
|
2009
|
2008
|
||||||
Convertible
debt
|
4,995,000 | 4,995,000 | ||||||
Warrants
|
6,899,353 | 6,899,353 | ||||||
Options
|
8,840,843 | 8,510,578 |
Years
ending March 31,
|
Operating
Leases
|
Capital
Lease
|
Debt
Maturities
|
Total
|
||||||||||||
2010
|
$ | 73,500 | $ | 2,600 | $ | 100,000 | $ | 176,100 | ||||||||
2011
|
2,600 | 75,000 | 77,600 | |||||||||||||
2012
|
2,600 | 2,600 | ||||||||||||||
2013
|
2,600 | 2,600 | ||||||||||||||
Total
|
$ | 73,500 | $ | 10,400 | $ | 175,000 | $ | 258,900 | ||||||||
Less
interest
|
(2,700 | ) | (1,700 | ) | (12,300 | ) | (16,700 | ) | ||||||||
Net
present value
|
70,800 | 8,700 | 162,700 | 242,200 | ||||||||||||
Less
current portion
|
(70,800 | ) | (2,000 | ) | (90,200 | ) | (163,000 | ) | ||||||||
Long-term
debt and lease obligation
|
$ | 0 | $ | 6,700 | $ | 72,500 | $ | 79,200 |
Three
Months Ended
March
31, 2009
|
Three
Months
Ended
March
31, 2008
|
|||||||
Revenues
|
100 | % | 100 | % | ||||
Cost
of revenues
|
19 | 27 | ||||||
Gross
profit
|
81 | 73 | ||||||
Research
and development
|
302 | 247 | ||||||
Sales
and marketing
|
154 | 96 | ||||||
General
and administrative expenses
|
417 | 348 | ||||||
Operating
loss
|
(792 | ) | (618 | ) | ||||
Other
income (expense), net
|
(3 | ) | 14 | |||||
Net
income (loss)
|
(795 | ) % | (604 | ) % |
Three
Months
Ended
March
31,
2009
|
Three
Months
Ended
March
31,
2008
|
Percent
Change
|
||||||||||
Laboratory
Service Revenues
|
$ | 31,200 | $ | 35,800 | (13 | %) | ||||||
Clinical
Service
Revenues
|
152,600 | 180,600 | (16 | %) | ||||||||
Total
Revenues
|
$ | 183,800 | $ | 216,400 | (15 | %) |
Three
Months
Ended
March
31,
2009
|
Three
Months
Ended
March
31,
2008
|
Percent
Change
|
||||||||||
Cost
of Laboratory Information Services revenues
|
$ | 35,600 | $ | 59,500 | (40 | %) | ||||||
Three
Months
Ended
March
31,
2009
|
Three
Months
Ended
March
31,
2008
|
Percent
Change
|
||||||||||
Laboratory
Information Services research and development
|
$ | 554,400 | $ | 534,100 | 4 | % | ||||||
Three
Months
Ended
March
31,
2009
|
Three
Months
Ended
March
31,
2008
|
Percent
Change
|
||||||||||
Sales
and Marketing
|
||||||||||||
Laboratory
Information Services
|
$ | 282,300 | $ | 204,900 | 38 | % | ||||||
Clinical
Services
|
1,400 | 3,200 | (56 | %) | ||||||||
Total
Sales and
Marketing
|
$ | 283,700 | $ | 208,100 | 36 | % | ||||||
Three
Months
Ended
March 31,
2009
|
Three
Months
Ended
March 31,
2008
|
Percent
Change
|
||||||||||
General
and administrative
|
||||||||||||
Laboratory
Information Services
|
$ | 597,600 | $ | 555,800 | 8 | % | ||||||
Clinical
Services
|
$ | 168,300 | 197,000 | (15 | %) | |||||||
Total
General and administrative
|
$ | 765,900 | $ | 752,800 | 2 | % | ||||||
Three
Months
Ended
March 31, 2009
|
Three
Months
Ended
March 31, 2008
|
Percent
Change
|
||||||||||
Laboratory
Information Services (Expense), net
|
$ | (4,600 | ) | $ | 30,200 |
*
|
||||||
Clinical
Services (Expense)
|
(100 | ) |
*
|
|||||||||
Total
interest income (expense)
|
$ | (4,700 | ) | $ | 30,200 |
*
|
||||||
*
not
meaningful
|
Three
Months
Ended
March
31,
2009
|
Three
Months
Ended
March
31,
2008
|
Percent
Change
|
||||||||||
Laboratory
Information Services net loss..
|
$ | (1,468,200 | ) | $ | (1,299,500 | ) |
15%
|
|||||
Clinical
Services net loss..
|
6,900 | (8,400 | ) |
*
|
||||||||
Total
Net Loss..
|
$ | (1,461,300 | ) | $ | (1,307,900 | ) |
12%
|
|||||
*
not
meaningful
|
Six
Months
Ended
March
31, 2009
|
Six
Months
Ended
March
31, 2008
|
|||||||
Revenues
|
100 | % | 100 | % | ||||
Cost
of revenues
|
19 | 35 | ||||||
Gross
profit
|
81 | 65 | ||||||
Research
and development
|
348 | 330 | ||||||
Sales
and marketing
|
154 | 90 | ||||||
General
and administrative expenses
|
391 | 518 | ||||||
Operating
loss
|
(812 | ) | (873 | ) | ||||
Other
income (expense), net
|
(2 | ) | 31 | |||||
Net
income (loss)
|
(814 | ) % | (842 | ) % |
Six
Months
Ended
March
31,
2009
|
Six
Months
Ended
March
31,
2008
|
Percent
Change
|
||||||||||
Laboratory
Service Revenues
|
$ | 59,700 | $ | 94,500 | (37 | %) | ||||||
Clinical
Service
Revenues
|
295,800 | 180,600 | (64 | %) | ||||||||
Total
Revenues
|
$ | 355,500 | $ | 275,100 | (29 | %) | ||||||
Six
Months
Ended
March
31,
2009
|
Six
Months
Ended
March
31,
2008
|
Percent
Change
|
||||||||||
Cost
of Laboratory Information Services revenues
|
$ | 69,100 | $ | 97,400 | (29 | %) | ||||||
Six
Months
Ended
March
31,
2009
|
Six
Months
Ended
March
31,
2008
|
Percent
Change
|
||||||||||
Laboratory
Information Services research and development
|
$ | 1,236,900 | $ | 906,600 | 36 | % | ||||||
Six
Months
Ended
March
31,
2009
|
Six
Months
Ended
March
31,
2008
|
Percent
Change
|
||||||||||
Sales
and Marketing
|
||||||||||||
Laboratory
Information Services
|
$ | 542,900 | $ | 243,600 | 123 | % | ||||||
Clinical
Services
|
4,100 | 3,200 | 28 | % | ||||||||
Total
Sales and Marketing
|
$ | 547,000 | $ | 246,800 | 122 | % |
Six
Months
Ended
March
31,
2009
|
Six
Months
Ended
March
31,
2008
|
Percent
Change
|
||||||||||
General
and administrative
|
||||||||||||
Laboratory
Information Services
|
$ | 1,072,300 | $ | 1,227,400 | (13 | %) | ||||||
Clinical
Services………………….
|
$ | 317,100 | 197,000 | 61 | % | |||||||
Total
General and administrative
|
$ | 1,389,400 | $ | 1,424,400 | 2 | % | ||||||
Six
Months
Ended
March
31,
2009
|
Six
Months
Ended
March
31,
2008
|
Percent
Change
|
||||||||||
Laboratory
Information Services (Expense), net
|
$ | (3,400 | ) | $ | 84,200 |
*
|
||||||
Clinical
Services (Expense)
|
(100 | ) | - |
*
|
||||||||
Total
interest income (expense)
|
$ | (3,500 | ) | $ | 84,200 |
*
|
||||||
*
not
meaningful
|
Six
Months
Ended
March
31,
2009
|
Six
Months
Ended
March
31,
2008
|
Percent
Change
|
||||||||||
Laboratory
Information Services net loss
|
$ | (2,892,500 | ) | $ | (2,290,100 | ) | 26 | % | ||||
Clinical
Services net loss
|
(700 | ) | (26,600 | ) | (97 | %) | ||||||
Total
Net Loss
|
$ | (2,893,200 | ) | $ | (2,316,700 | ) | 25 | % | ||||
Exhibit
Number
|
Exhibit Title
|
10.1
|
Senior
Secured Convertible Promissory Note, dated March 30, 2009, by and between
the Company and Brandt Ventures, GP. Incorporated by reference
to the Registrant’s Current Report on Form 8-K filed with the Securities
and Exchange Commission on April 3, 2009 (File Number
000-26285).
|
10.2
|
Senior
Secured Convertible Promissory Note, dated March 30, 2009, by and between
the Company and SAIL Venture Partners, LP. Incorporated by reference to
the Registrant’s Current Report on Form 8-K filed with the Securities and
Exchange Commission on April 3, 2009 (File Number
000-26285).
|
31.1
|
Certification
of Principal Executive Officer pursuant to Securities Exchange Act Rules
13a-14(a) and 15d-14(a) as adopted pursuant to section 302 of the
Sarbanes-Oxley Act of 2002.
|
31.2
|
Certification
of Principal Financial Officer pursuant to Securities Exchange Act Rules
13a-14(a) and 15d-14(a) as adopted pursuant to section 302 of the
Sarbanes-Oxley Act of 2002.
|
32.1
|
Certification
of Principal Executive Officer and Principal Financial Officer pursuant to
18 U.S.C. Section 1350, as adopted pursuant to section 906 of the
Sarbanes-Oxley Act of
2002.
|
CNS Response, Inc. | |||
Date:
May 15, 2009
|
|
/s/ George Carpenter | |
By: | George Carpenter | ||
Its: | Chief Executive Officer | ||
(Principal
Executive, Financial and
Accounting Officer)
|